panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2 -activating mutations.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Sarah Cannon, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Institut Bergonié, Vall d'Hebron Institute of Oncology, City Of Hope National Medical Center, National Cancer Center Hospital East, Macquarie University, Bayer (Switzerland), Bayer (Germany), Bayer (Italy), Agostino Gemelli University Polyclinic
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Bayer
OpenAlex ID: W4410822773